You just read:

Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP

News provided by

Rigel Pharmaceuticals, Inc.

20 Oct, 2016, 07:00 ET